Recombinant Proteins

Proteins prepared by recombinant DNA technology.
DrugDrug NameDrug Indication
DB00004Denileukin diftitoxFor treatment of cutaneous T-cell lymphoma
DB00049RasburicaseFor treatment of hyperuricemia, reduces elevated plasma uric acid levels (from chemotherapy)
DB00053ImigluceraseFor the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
DB00088AlgluceraseFor the treatment of Gaucher's disease (deficiency in glucocerebrosidase)
DB00092AlefaceptAs an immunosuppressive drug, Alefacept can be used for treatment of moderate to severe chronic plaque psoriasis
DB04925DesmoteplaseInvestigated for use/treatment in cerebral ischemia and strokes.
DB05319Oportuzumab monatoxInvestigated for use/treatment in bladder cancer and head and neck cancer.
DB05332RomiplostimTreatment of chronic immune thrombocytopenic purpura.
DB05584PraconaseInvestigated for use/treatment in spinal cord injuries.
DB05718Maxy-G34Investigated for use/treatment in adverse effects (chemotherapy) and neutropenics.
DB05793PRO-542Investigated for use/treatment in acquired immune deficiency syndrome (AIDS) and aids-related infections, HIV infection, and pediatric indications.
DB05942GI-5005Investigated for use/treatment in hepatitis (viral, C).
DB06372RilonaceptRilonacept is currently used in the treatment of cryopyrin-associated periodic syndrome. In May 2012, an advisory panel for the FDA voted 11-0 against the use of Rilonacept for the treatment of gout.
DB06399AtaciceptInvestigated for use/treatment in autoimmune diseases, systemic lupus erythematosus, rheumatoid arthritis, multiple myeloma, lymphoma (non-hodgkin's), and leukemia (lymphoid).
DB06495OnerceptInvestigated for use/treatment in psoriasis and psoriatic disorders and crohn's disease.
DB06576BaminerceptInvestigated for use/treatment in rheumatoid arthritis.
DB06611PegsunerceptInvestigated for use/treatment in rheumatoid arthritis.
DB08876Taliglucerase alfaFor the treatment of adult Type 1 Gaucher disease.
DB08885AfliberceptThe opthalmic agent is used for the treatment of neovascular (wet) age-related mascular degeneration (AMD) and macular edema following central retinal vein occulsion (CRVO). The systemic injection, known as ziv-aflibercept, in combination with 5-fluorouracil, leucovorin, irinotecan-(FOLFIRI), is for the treatment of metastatic colorectal cancer that is resistant to or progressed following treatment with oxaliplatin.
DB09043AlbiglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09045DulaglutideIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
DB09051Elosulfase alfaVimizim is a hydrolytic lysosomal glycosaminoglycan (GAG)-specific enzyme indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).
DB09066Corifollitropin alfaControlled ovarian stimulation [L2273] in cases of women who are undergoing fertility treatment to stimulate the development of more than one mature egg simultaneously in the ovaries in combination with a gonadotrophin-releasing hormone (GnRH) antagonist (a type of medicine also used in fertility treatments)[L2270].
DB09105Asfotase alfaIndicated for the treatment of patients with perinatal/infantile and juvenile onset hypophosphatasia (HPP).
DB09109Turoctocog alfaTuroctocog alfa is indicated for the treatment and prophylaxis of bleedings in patients presenting hemophilia A.[L1105] The treatment with turoctocog alfa is related with its use to control bleeding episodes or as a perioperative management.[L1106] Hemophilia A is a hereditary hemorrhagic disorder generated by the congenital deficit of the coagulation factor VIII. This disease is manifested as excessive spontaneous or trauma-driven bleeding. The coagulation factor VIII is a robust initiator of thrombin which is later required for the generation of fibrin to form a platelet plug and its gene is expressed in the X chromosome.[A31505]
DB11690VonapanitaseNot Available
DB12056TrebananibNot Available
DB12118SotaterceptNot Available
DB12132Vanutide cridificarNot Available
DB12330BlisibimodNot Available
DB12349DulanerminNot Available
DB12460ConberceptNot Available
DB12699BalugrastimNot Available
DB13999Moroctocog alfaMoroctocog Alfa is approved by Health Canada for the control and prevention of hemorrhagic episodes and for routine and surgical prophylaxis in patients with hemophilia A (congenital factor VIII deficiency or classic hemophilia). Moroctocog Alfa is also approved by the European Medicines Agency for the treatment and prophylaxis of bleeding in patients with Haemophilia A (congenital factor VIII deficiency).
DB09329Antihemophilic Factor (Recombinant), PEGylatedFor the management of hemophilia A (congenital factor VIII deficiency) [FDA label], [A32064]. This medication is a human antihemophilic factor indicated in adolescent and adult patients (12 years and older) with hemophilia A (congenital factor VIII deficiency). It is also used for on-demand treatment and control of bleeding and routine prophylaxis of bleeding episodes. It is not indicated for the treatment of von Willebrand disease [FDA label].
DB14712ElapegademaseElapegademase is approved for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.[L4654] This condition was previously treated by the use of pegamedase bovine as part of an enzyme replacement therapy.[L4655] ADA-SCID is a genetically inherited disorder that is very rare and characterized by a deficiency in the adenosine deaminase enzyme. The patients suffering from this disease often present a compromised immune system. This condition is characterized by very low levels of white blood cells and immunoglobulin levels which results in severe and recurring infections.[L4656]
DB14738Turoctocog alfa pegolTuroctocog alfa pegol (N8-GP) is indicated for use in adults and children of all ages with hemophilia A (congenital factor VIII deficiency) for routine prophylaxis in reducing the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes, and the perioperative management of bleeding [F3649].
DB14988DalanterceptNot Available
DB15045IpafriceptNot Available
DB15095LeridistimNot Available
DB15160AsunerceptNot Available
DB15313DAS-181Not Available
DB15336Valanafusp alfaNot Available
DB15386ALT-801Not Available
DB05305Cintredekin BesudotoxInvestigated for use/treatment in brain cancer.
DB11608Eftrenonacog alfaIndicated for the treatment and prophylaxis of bleeding in patients of all age with haemophilia B (congenital factor IX deficiency).
DB11727EndostarNot Available
DB12258Abicipar PegolNot Available
DB12281LuspaterceptNot Available
DB12950AlbusomatropinNot Available
DB13884Albutrepenonacog alfaUnder the EMA and FDA, rIX-RFP is indicated in the treatment of hemophilia B.[L2306] For Health Canada, rIX-FRP is also indicated to prevent or reduce bleeding episodes.[L2305] Hemophilia B is the second most common type of hemophilia. It is a rare inherited bleeding disorder caused by reduced or absent levels of factor IX (FIX). The FIX is a vitamin K-dependent plasma protease that when activated is involved in the blood coagulation cascade.[A32551] The hemophilia B is caused by mutations in the _FIX_ gene which can cause different phenotypes. The severe form is characterized by the presence of spontaneous and recurring bleeds into the joints and muscles and excessive bleeding after trauma or surgery.[A32552]
DB14731TagraxofuspTagraxofusp is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and pediatric patients over 2 years old. This treatment allows an alternative for the previous intense treatment which consisted of intensive chemotherapy followed by bone marrow transplantation.[L4893] BPDCN is a rare hematologic malignancy derived from plasmacytoid dendritic cells. It is characterized by the significantly increased expression of cells expressing CD4/CD56/CD123 and other markers restricted to plasmacytoid dendritic cells and a lack of expression of lymphoid, natural killer or myeloid lineage-associated antigens.[A40274] A key feature of the malignant cells is the overexpression of CD123, also known as interleukin-3 receptor, and the constant requirement of IL-3 for survival.[L4897]
DB15162PegilodecakinNot Available
DrugDrug NameTargetType
DB00004Denileukin diftitoxInterleukin-2 receptor subunit alphatarget
DB00004Denileukin diftitoxCytokine receptor common subunit gammatarget
DB00004Denileukin diftitoxInterleukin-2 receptor subunit betatarget
DB00049RasburicaseUric acidtarget
DB00092AlefaceptT-cell surface antigen CD2target
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Btarget
DB00092AlefaceptComplement C1r subcomponenttarget
DB00092AlefaceptComplement C1q subcomponent subunit Atarget
DB00092AlefaceptComplement C1q subcomponent subunit Btarget
DB00092AlefaceptComplement C1q subcomponent subunit Ctarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor III-Atarget
DB00092AlefaceptHigh affinity immunoglobulin gamma Fc receptor Itarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-atarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-btarget
DB00092AlefaceptLow affinity immunoglobulin gamma Fc region receptor II-ctarget
DB05319Oportuzumab monatoxEpithelial cell adhesion moleculetarget
DB05332RomiplostimThrombopoietin receptortarget
DB05793PRO-542Free fatty acid receptor 4target
DB06372RilonaceptInterleukin-1 betatarget
DB06372RilonaceptInterleukin-1 alphatarget
DB06372RilonaceptInterleukin-1 receptor antagonist proteintarget
DB06495OnerceptTumor necrosis factortarget
DB08876Taliglucerase alfaGlucocerebrosidetarget
DB08885AfliberceptVascular endothelial growth factor Atarget
DB08885AfliberceptPlacenta growth factortarget
DB08885AfliberceptVascular endothelial growth factor Btarget
DB09043AlbiglutideGlucagon-like peptide 1 receptortarget
DB09045DulaglutideGlucagon-like peptide 1 receptortarget
DB09051Elosulfase alfaN-acetylgalactosamine-6-sulfataseenzyme
DB09066Corifollitropin alfaFollicle-stimulating hormone receptortarget
DB09105Asfotase alfaSphingosine 1-phosphate receptor 1target
DB09105Asfotase alfaPyrophosphatetarget
DB09109Turoctocog alfaCoagulation factor IXtarget
DB09109Turoctocog alfaCoagulation factor Xtarget
DB09109Turoctocog alfaProthrombintarget
DB12118SotaterceptActivin receptor type-2Atarget
DB13999Moroctocog alfaCoagulation factor Xtarget
DB13999Moroctocog alfaPhytanoyl-CoA dioxygenase, peroxisomaltarget
DB13999Moroctocog alfaCoagulation factor IXtarget
DB13999Moroctocog alfaAsialoglycoprotein receptor 2target
DB13999Moroctocog alfa78 kDa glucose-regulated proteintarget
DB13999Moroctocog alfaCalreticulintarget
DB13999Moroctocog alfaCalnexintarget
DB13999Moroctocog alfaProtein ERGIC-53target
DB13999Moroctocog alfaProlow-density lipoprotein receptor-related protein 1target
DB13999Moroctocog alfaMultiple coagulation factor deficiency protein 2target
DB13999Moroctocog alfavon Willebrand factortarget
DB13999Moroctocog alfaProthrombinenzyme
DB13999Moroctocog alfaVitamin K-dependent protein Cenzyme
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factortarget
DB09329Antihemophilic Factor (Recombinant), PEGylatedvon Willebrand factorcarrier
DB14738Turoctocog alfa pegolVitamin K-dependent protein Cenzyme
DB14738Turoctocog alfa pegolCoagulation factor Xenzyme
DB14738Turoctocog alfa pegolCoagulation factor IXtarget
DB14738Turoctocog alfa pegolCoagulation factor Xtarget
DB14738Turoctocog alfa pegolProthrombintarget
DB14738Turoctocog alfa pegolvon Willebrand factorcarrier
DB05305Cintredekin BesudotoxInterleukin-13target
DB13884Albutrepenonacog alfaCoagulation factor Xtarget
DB13884Albutrepenonacog alfaCoagulation factor VIIIenzyme
DB14731TagraxofuspInterleukin-3 receptor subunit alphatarget
DB14731TagraxofuspADP-ribosylation factor-like protein 2target